Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
The MICs of LBM415, a new peptide diformylase inhibitor, were evaluated and ranged from 0.03 to 4.0 microg/ml for 300 pneumococci, irrespective of their beta-lactam, macrolide, and quinolone susceptibilities. By comparison, vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin were also active, with MICs </=2.0 microg/ml. Gatifloxacin and moxifloxacin were the most active quinolones tested, while the MICs of the beta-lactams rose with those of penicillin G. LBM415 at two times the MIC was bactericidal (99.9% killing) against six strains after 24 h.
Ednie
Lois M
LM
Department of Pathology, Penn State Hershey Medical Center, 500 University Dr., H160, Hershey, PA 17033, USA. pappelbaum@psu.edu
Pankuch
Glenn
G
Appelbaum
Peter C
PC
D000581:Amidohydrolases / Q000037:antagonists & inhibitors*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000494:pharmacology*; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; C487638:NVP PDF 713; D010455:Peptides; D000581:Amidohydrolases; C084507:peptide deformylase